Overview

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Status:
Active, not recruiting

Trial end date:
2024-04-17

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma

Phase:

Phase 3

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborators:

Exelixis
Ono Pharmaceutical Co. Ltd

Treatments:

Antibodies, Monoclonal
Ipilimumab
Nivolumab
Sunitinib